Apollomics Revenue and Competitors
Estimated Revenue & Valuation
- Apollomics's estimated annual revenue is currently $3.1M per year.
- Apollomics's estimated revenue per employee is $77,500
- Apollomics's total funding is $239M.
Employee Data
- Apollomics has 40 Employees.
- Apollomics grew their employee count by -27% last year.
Apollomics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Financial Officer | Reveal Email/Phone |
2 | SVP Biostatistics and Data Management | Reveal Email/Phone |
3 | VP Finance, Corporate Controller | Reveal Email/Phone |
4 | VP, Clinical Operations | Reveal Email/Phone |
5 | VP, Clinical Development | Reveal Email/Phone |
6 | Head Drug Safety, Pharmacovigilance and Risk Management | Reveal Email/Phone |
7 | Co-Founder, Executive Director, Chairman and CEO | Reveal Email/Phone |
8 | Co-Founder, Executive Director and President | Reveal Email/Phone |
9 | Chief Medical Officer | Reveal Email/Phone |
10 | Financial Reporting Manager | Reveal Email/Phone |
Apollomics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $15640M | 246141 | N/A | N/A | $109.8B |
What Is Apollomics?
Formerly known as CBT Pharmaceuticals. At Apollomics, we are a purpose driven company imagining a world without cancer. We let science drive our decision making to advance our programs. We believe in the power of partnerships to enhance our pipeline and broaden the patient populations we serve. Apollomics is committed to the discovery and development of oncology combination therapies. We believe that combination regimens can achieve clinically meaningful, durable responses that will allow us to enhance outcomes for patients. We have in-licensed our assets from multiple partners and built strong collaborations to advance our pre-clinical and clinical development programs. When developing an asset, we begin with rigorous IND-enabling studies to establish sound mechanistic and scientific rationale and guide our development path. This path may be as a monotherapy, a combination therapy, or both. While our ultimate goal is to study each of our assets in combination with other agents, we have developed a broad portfolio of single agent and combination trials.
keywords:N/A
$239M
Total Funding
40
Number of Employees
$3.1M
Revenue (est)
-27%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Apollomics News
Prior to Apollomics, Mr. Cheung was CFO at KBP Biosciences, Inc. and served as SVP and CFO at SciClone Pharmaceuticals, Inc. where he led the...
... inhibitors market report also offers information on several market vendors, including Amgen Inc., Apollomics Inc., AstraZeneca Plc,...
Premium Apollomics, Inc., an incubator project by US healthcare fund manager OrbiMed Asia, announced on Friday that it has raised $124.2 million in a Series C round of financing led by China’s Ping An Insurance Group’s investment vehicle Ping An Capital and joined by a slew of undivulged new an ...
Apollomics has raised $100 million to fund a multifront oncology clinical trial program while moving its headquarters from China to California. The series B round sets Apollomics up to advance its c-Met inhibitor and pipeline of other clinical-phase assets. Sponsored by Agilent Technologies Ho ...
Apollomics, Inc. (fka CBT Pharmaceuticals, Inc.), a Foster City, CA-based innovative biopharmaceutical company committed to the discovery and development of oncology combination therapies, raised $100m in a Series B financing. The round was led by CMB International, a subsidiary of China Mercha ...
Other Companies in Foster City
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $5.8M | 40 | 3% | N/A |
#2 | $4.4M | 41 | 28% | $36.1M |
#3 | $5M | 42 | -26% | N/A |
#4 | $6.8M | 44 | -66% | $25M |
#5 | $6.4M | 51 | 42% | $15M |